Arblast USA
Statement regarding business transfer contract submitted to the district court in Kobe
The following is a statement submitted to the district court in Kobe by Zen Kitagawa and Mr. Inoue, who was acting as the representative.
Immediately after hearing the fact that Alblast and Alblast USA have signed a business transfer agreement, the Kobe Advanced Medical Promotion Foundation filed a lawsuit to seize a patent. At that time, Alblast decided to submit a statement at the extraordinary general meeting of shareholders, and it will be the statement submitted by Mr. Inoue and Zen Kitagawa, who were acting representatives at that time.
In this, it is clearly written as follows.
The patent of our company Alblast has already been approved by transferring the business to Alblast USA at the general meeting of shareholders in December 2010, and the business transfer contract was concluded in December.
Therefore, even if this patent right is sold this time, the purchaser does not have the right to carry out research and development because the business transfer agreement has already been concluded.
From these words, you can recognize the fact that the business transfer has already been decided at the general meeting of shareholders and the business transfer has been concluded.
Normally, the business transfer agreement was signed for the rehabilitation of Alblast, so the Kobe Advanced Medical Promotion Foundation does not have the right to seize.
However, the Foundation ignored it, and as Mr. S, who is Shigeru Kinoshita's agent, said, the Foundation and Shigeru Kinoshita colluded and led Alblast to bankruptcy because it wanted a patent. Is it a trial for the sake of wanting? Or is it because JCR and the Foundation have bankruptcy like Hyena, as in all Kitagawa emails? Or, as Zen Kitagawa and a former employee of the Foundation said, Yoshiko Nakajima, the wife of Stemcell Science's Nakajima and an employee of the Foundation, profited from Stemcell Science's delinquent rent (about 30 million yen). Considering the fact that I was telling the bad publicity of myself and my husband to the Foundation executives because I hated because I knew the facts that had been erased in conflict, it seems that we hate it, but it is not harassing. Is it? I don't know which one, but it's unlikely that the Foundation, the city's affiliate, would normally seize the patents of the company in the reverse merger's DD. Everyone was talking.
All of the above is evidence.
If you would like to know more, please click below.
This patent of our company Alblast has already been approved by transferring the business to Alblast USA at the general meeting of shareholders in December 2010, and the business transfer contract was concluded in December.
Therefore, even if this patent right is sold this time, the purchaser does not have the right to carry out research and development because the business transfer agreement has already been concluded.
The name of the JPO was not changed to Alblast USA Inc., only because it was delayed due to the earthquake in March, and the right to change the name was also transferred (to Alblast USA). I have. (However, if the company is not listed, the name will be changed to Alblast again.) Therefore, Alblast USA is currently planning to file a lawsuit against the purchaser if the sale is decided. We are here.
In order to avoid such problems, please stop selling this patent based on the business transfer agreement that has already been concluded. Finally, we believe that this patent is a patent that was granted by the investment of many shareholders of Alblast, and is a crystal of the blood and sweat of the shareholders.
At the same time, the patent is capable of relieving corneal damage in many visually impaired patients, and Alblast USA Inc. has now filed this advanced medical application within the University of Pittsburgh after listing. , We are preparing to provide patient relief, but with the sale of this patent, even these patient reliefs will run into a deadlock.
Please be aware of the fact that this patent has already been transferred to Alblast USA Inc. and our company Alblast has no rights.
